Financials data is unavailable for this security.
View more
Year on year Beam Therapeutics Inc grew revenues 520.01% from 60.92m to 377.71m while net income improved from a loss of 289.09m to a smaller loss of 132.53m.
Gross margin | -- |
---|---|
Net profit margin | -41.07% |
Operating margin | -52.25% |
Return on assets | -11.67% |
---|---|
Return on equity | -18.29% |
Return on investment | -13.84% |
More ▼
Cash flow in USDView more
In 2023, Beam Therapeutics Inc increased its cash reserves by 81.09%, or 199.09m. Cash Flow from Financing totalled 276.45m or 73.19% of revenues. In addition the company used 149.20m for operations while cash from investing totalled 71.84m.
Cash flow per share | -1.49 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.58 |
---|---|
Tangible book value per share | 9.58 |
More ▼
Balance sheet in USDView more
Current ratio | 5.69 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼